

## Range of International Normalised Ratio (INR) recommended for specific applications of warfarin therapy

The table below is based on the *Consensus Guidelines for Warfarin Therapy* (Australasian Society of Thrombosis and Haemostasis, 2000).

<b>Condition</b>	<b>INR range</b>
<b>Preventing deep-vein thrombosis</b> (high-risk patients, such as those who have had hip replacement)	<b>2.0–3.0</b>
<b>Therapy after deep-vein thrombosis or pulmonary embolism</b>	<b>2.0–3.0</b>
<b>Preventing systemic embolism</b>	
Atrial fibrillation	<b>2.0–3.0</b>
Valvular heart disease	<b>2.0–3.0</b>
After myocardial infarction	<b>2.0–3.0</b>
Tissue heart valves (first 3 months)	<b>2.0–3.0</b>
<b>Bi-leaflet mechanical heart valve (aortic)</b>	<b>2.5–3.5</b>
<b>Mechanical prosthetic heart valve (high risk)</b>	<b>3.0–4.5</b>
<b>Preventing recurrence of myocardial infarction</b>	<b>3.0–4.5</b>
<b>Thrombosis in antiphospholipid antibody syndrome</b>	<b>3.0–4.5</b>